Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ELTX, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| AMP KRAS Vaccine ELI-002 | Pancreatic Ductal Adenocarcinoma | Phase 1/2 · NCT05726864 | Active not recruiting |
| mFOLFIRINOX | Pancreatic Cancer | Phase 1 · NCT07671339 | Recruiting |
Also used in these trials (approved or third-party drugs, not ELTX's own candidates): Tislelizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ELTX holds $23.5M in cash and short-term investments (as of Jun 30, 2026) and burns about $9.9M/quarter from operations, an estimated runway of 7.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 65 · High
The Company’s losses from operations, negative operating cash flows and accumulated deficit, as well as the additional capital needed to fund operations for at least twelve months following the issuance of the condensed consolidated financial statements, raise substantial doubt about the Company’s ability to continue a10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ELTX files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ELTX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →